Compare AVLN & UMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | UMH |
|---|---|---|
| Founded | N/A | 1968 |
| Country | United States | United States |
| Employees | N/A | 540 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | N/A |
| Metric | AVLN | UMH |
|---|---|---|
| Price | $28.73 | $15.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.75 |
| AVG Volume (30 Days) | 258.9K | ★ 410.3K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | ★ 5.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.51 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $203.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $13.93 |
| 52 Week High | $33.32 | $16.98 |
| Indicator | AVLN | UMH |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 43.82 |
| Support Level | $26.68 | $14.76 |
| Resistance Level | $29.59 | $15.72 |
| Average True Range (ATR) | 1.99 | 0.30 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 61.44 | 7.69 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
UMH Properties Inc together with its subsidiaries, is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents. The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, it sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for its sites and homes, where the company is the lessor.